Vaccine

Syvazul® BTV 3 suspension for injection

Injectable suspension for sheep and cattle.
Vaccine against bluetongue serotype 3 authorised for emergency use in the Netherlands, Belgium, Germany, Austria, Spain, Portugal, Sweden, Italy, Denmark in accordance with Art. 110 (2) of Regulation (EU) 2019/6. And in France in sheep.
Syvazul BTV3 is also approved for emergency use in the UK and in Switzerland.

Warning! Syvazul BTV3 is currently authorised for emergency use under Article 110(2) of Regulation (EU) 2019/6 in the following countries: the Netherlands, Belgium, Germany, Austria, Spain, Portugal, Sweden, Italy, Denmark. Syvazul BTV3 is authorised in France (art110 - 2) in sheep. Syvazul BTV3 is also approved for emergency use in the United Kingdom and Switzerland. The information on this page is only indicative of the current regulations in these countries. For more information, if your country is not covered by this emergency use authorization, please contact our export department: silvia.carrera@syva.es.

Quick product information

Active ingredient(s)	Posology*	Waiting time	Packaging
Bluetongue virus, serotype 3 (BTV-3), strain BTV-3/NET2023, inactivated ≥ 106,9 CCID50	Sheep: Subcutaneous use. from 3 months – Primary vaccination: one dose of 2 ml. Cattle: Intramuscular use. from 2 months of age – Primary vaccination: two doses of 4 ml at 3 weeks intervals. More information: click on the red block “see more about this product”.	Zero days.	Vials 80 ml and 200 ml

Active ingredient(s)

Posology*

Waiting time

Packaging

Bluetongue virus, serotype 3 (BTV-3), strain BTV-3/NET2023, inactivated ≥ 106,9 CCID50

Sheep: Subcutaneous use.
from 3 months – Primary vaccination: one dose of 2 ml.

Cattle: Intramuscular use.
from 2 months of age – Primary vaccination: two doses of 4 ml at 3 weeks intervals.

More information: click on the red block “see more about this product”.

Zero days.

Vials 80 ml and 200 ml

Country Availability

Netherlands, Belgium, Germany, United Kingdom, Austria, Spain, Portugal, Sweden, Denmark, Italy, Switzerland, France.

If your country is not listed, please contact our export team.

Contactar

View more about this product

Active ingredient(s)

Bluetongue virus, serotype 3 (BTV-3), strain BTV-3/NET2023, inactivated ≥ 106.9 CCID50*.
*CCID50: 50% infectious dose in cell culture, determined before inactivation.
Adjuvants:
Aluminium hydroxide (Al3+) 2.08 mg
Purified saponin (Quil-A) from Quillaja saponaria 0,2 mg
Excipient:
Thiomersal 0,1 mg

Indications

Sheep:
For active immunisation of sheep to prevent mortality and reduce viraemia, clinical signs and lesions caused by bluetongue virus serotype 3.
Onset of immunity: 28 days after completion of the primary vaccination programme.
Duration of immunity has not been established.
Cattle:
For active immunisation of cattle against BTV serotype 3.
The onset and duration of immunity has not been established.

Special precautions

Vaccinate healthy animals only.
When used in other domestic or wild ruminant species considered to be at risk of infection, caution should be applied. It is recommended to test the vaccine in a small number of animals before mass vaccination. The degree of efficacy in other species may differ from that in sheep and cattle.
No information is available on the use of the vaccine in sheep and cattle with maternal antibodies.

Posology

Sheep:
Subcutaneous use.
Administer subcutaneously to sheep from 3 months of age according to the following scheme:
– Primary vaccination: administer one dose of 2 ml.
– Repeat vaccination: administer a dose of 2 ml at 12 months of age.

Cattle (These recommendations have been extrapolated from vaccines with other serotypes (BTV1, 4, 8)):
Intramuscular use.
Administer intramuscularly to cattle from 2 months of age in naive animals or from 3 months of age in calves born to immune cattle, according to the following schedule:
– Primary vaccination: administer two doses of 4 ml at 3 week intervals.
– Repeat vaccination: administer one dose of 4 ml at 12 months of age.